Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

Chronic Lymphocytic Leukemia (CLL) and White Blood Cell Count

Diagnostic Criteria and WBC Elevation

  • The diagnosis of CLL is established by a sustained increase of peripheral blood lymphocytes ≥ 5 × 10^9/L (5,000/μL) not explained by other clinical disorders 2, 3
  • CLL is characterized by the predominance of small, morphologically mature lymphocytes in the blood smear 2
  • The composite immunophenotype of these cells is typically CD5+, CD19+, CD20+ (low), CD23+, sIg low, CD79b low, FMC7– which distinguishes CLL from other CD5+ B-cell lymphomas 2

Degree of WBC Elevation in CLL

  • Unlike in acute leukemias, even markedly elevated WBC counts in CLL (hyperleukocytosis) rarely cause symptoms related to leukocyte aggregates 3, 4
  • The absolute lymphocyte count should not be used as the sole indicator for treatment, despite sometimes reaching very high levels 3, 5

Clinical Significance of WBC Elevation

  • Treatment decisions should be based on disease-related symptoms and progressive disease rather than absolute lymphocyte count alone 3, 4
  • Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months may be an indication for treatment 3
  • Factors contributing to lymphocytosis other than CLL (e.g., infections) should be excluded before initiating treatment 3

Monitoring WBC in CLL

  • For patients not requiring treatment (watch and wait approach), blood cell counts should be monitored every 3-6 months 1, 2
  • For patients on treatment, complete blood counts with differential should be performed regularly to assess response 3, 4
  • A complete remission requires peripheral blood lymphocytes below 4 × 10^9/L (4,000/μL) after completion of therapy 4

Important Caveats

  • The presence of an elevated WBC count alone, without other symptoms or complications, is not an indication for treatment in CLL 3, 4
  • Treatment should be initiated based on disease-related symptoms or progressive disease rather than the absolute lymphocyte count 3, 4